PFE Income Statement

Click line-items for a historical chart and %
Revenues 13.5B
Costs and expenses:
Cost of sales 2.65B
Selling, informational and administrative expenses 3.59B
Research and development expenses 1.8B
Amortization of intangible assets
Acquisition-related in-process research and development charges
Restructuring charges and certain acquisition-related costs 138M
Other deductions--net 170M
Income from continuing operations before provision for taxes on income 3.92B
Provision for taxes on income 1.16B
Income from continuing operations 2.76B
Discontinued operations:
Income from operations--net of tax
Gain on sale of discontinued operations--net of tax
Discontinued operations--net of tax 4M
Net income before allocation to noncontrolling interests 2.77B
Less: Net income attributable to noncontrolling interests 15M
Net income attributable to Pfizer Inc. 2.75B
Earnings per share--basic:
Income from continuing operations attributable to Pfizer Inc. common shareholders 0.38
Discontinued operations--net of tax (in dollars per share) 0
Net income attributable to Pfizer Inc. common shareholders (in dollars per share) 0.38
Earnings per share--diluted:
Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share) 0.38
Discontinued operations--net of tax (in dollars per share) 0
Net income attributable to Pfizer Inc. common shareholders (in dollars per share) 0.38
Weighted-average shares used to calculate earnings per common share:
Basic (in shares) 7.19B
Diluted (in shares) 7.27B
Cash dividends paid per common share (in dollars per share) 0.24

Entities mentioned with PFE

View All Entities